IP is key to beating pandemic, say IP5 members
The European, Korean, and Japanese patent offices have said collaboration between IP authorities will be key to defeating COVID-19.
The remarks came in joint statements published today, June 17, by the European Patent Office (EPO) with its IP5 partners, the Japan Patent Office (JPO) and the Korean Intellectual Property Office (KIPO).
IP5 is a group of the world’s five biggest patent offices, and also includes the US Patent and Trademark Office and the Chinese National Intellectual Property Administration.
“The EPO and the KIPO firmly believe that innovation is the key to putting an end to the coronavirus pandemic and rebuilding the global economy and trade,” one of the statements said.
The JPO, meanwhile, pledged to “continue to support [researchers’] efforts in developing technological solutions to this global challenge by offering access to patent information on technologies, through our free public patent databases”.
Each statement affirmed the importance of IP to fostering the innovation that IP5 believe will be key to finding definitive solutions to the COVID-19 pandemic.
The message comes amid debates over compulsory licensing and the exclusivity rewards enjoyed by pharmaceutical companies.
Speaking to LSPN Connect earlier this week, UK Intellectual Property Office CEO Tim Moss acknowledged the “theoretical risk” that IP could be used to restrict access to key technologies.
But this has not happened so far, he argued: “What we’re seeing in practice is some amazing collaborations ... it’s fantastic to see how the IP regime has responded to the pandemic.”
Moss added that the debate around IP’s place in fighting COVID-19 has had a positive impact insofar as it “put IP on the table and got people talking about it”.
In its statement, the Japanese office also cited its “open licensing database” where businesses can search for available technologies.
The latest releases follow similar joint statements issued by the EPO alongside the USPTO and CNIPA in April and June, respectively.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk